The role of nevirapine in the treatment of HIV-1 disease (Q34515604)

2 August 2017

1 reference

title

The role of nevirapine in the treatment of HIV-1 disease (English)

1 reference

2 August 2017

1 reference

Podzamczer D

1

1 reference

PubMed ID

11825335

2 August 2017

Fumero E

series ordinal

2

1 reference

PubMed ID

11825335

2 August 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

Expert Opinion on Pharmacotherapy

2 August 2017

1 reference

2 August 2017

2

1 reference

2 August 2017

12

1 reference

2 August 2017

2065-2078

1 reference

A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site

2 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.2065

Inhibition of HIV-1 reverse transcriptase and virus replication by a non-nucleoside dipyridodiazepinone BI-RG-587 (Nevirapine)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.2065

High-performance liquid chromatography and photoaffinity crosslinking to explore the binding environment of nevirapine to reverse transcriptase of human immunodeficiency virus type-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.2065

The treatment of tuberculosis in HIV-infected persons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.2065

Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.2065

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.2065

Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.2065

Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.2065

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.2065

A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.2065

Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.2065

Sequencing antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.2065

Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.2065

Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the Scan Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.2065

10.1517/14656566.2.12.2065

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11825335